During the MEDICA exhibition in Düsseldorf, Germany, on November 18, Salignostics present for the first time the world’s first saliva rapid pregnancy test, the SaliStick.
Salistick provides new and improved user experience and high accuracy for early pregnancy detection in the home or on the go. The kit is based on Salignostics revolutionary technology, which detects the pregnancy hormone β-hCG in saliva. The SaliStick has similar accuracy to the leading urine-based pregnancy test but is far less awkward. While there are over 50 brands of pregnancy tests, they are all urine or blood-based. The global market for pregnancy tests is about $ 2 billion annually, with 840 million tests sold annually.
In the pipeline are rapid self-diagnostics tests for malaria, Helicobacter pylori (H.Pylori), and Cardiac Risk.
Established in 2016, Salignostics has developed a novel technology that utilizes saliva for lateral flow immunoassay applications. Salignostics’ vision is to transform the next generation of in-vitro diagnostics by developing easy, clean, safe, low-cost, accessible and reliable saliva-based products.
The Salignostics team is comprised of experts in the fields of saliva research, Omer Deutsch, Raluca Cohen, and Aaron Palmon, from the Hebrew University Medical School. backed by experienced managers in tech development, and business development, Yoav Noyman, and Guy Krief. Max Herzberg chairs their advisory board.
Non-invasive, simple and accessible diagnostics is considered a vital goal as it allows for accurate monitoring of health status, disease onset, and progression, as well as treatment outcomes. Saliva is the optimal diagnostic body-fluid for non-invasive diagnostic modalities. However, due to technological hurdles, almost no Rapid Diagnostic Testing (RDT) utilizing saliva, are available.